BRIEF-Successful CANTOS Inflammation Trial supports rationale for Resverlogix' ongoing betonmace trial
August 29, 2017 at 15:48 PM EDT
* under CANTOS trial treatment with Resverlogix' apabetalone has demonstrated a reduction in inflammatory mediator il-6 by 29 percent Source text for Eikon: Further company coverage:
